iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)																		1 Months Ended		2 Months Ended	3 Months Ended				4 Months Ended	6 Months Ended		8 Months Ended	12 Months Ended
Stockholders' Equity (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2020	Jun. 17, 2020	May 13, 2020	Mar. 19, 2020	Oct. 31, 2019	Oct. 29, 2019	Oct. 28, 2019	Jun. 26, 2018	Jun. 20, 2018	Jan. 26, 2018	Nov. 27, 2017	Feb. 23, 2017	Apr. 13, 2016	Apr. 07, 2016	Jan. 25, 2016	Jan. 13, 2016	Aug. 31, 2020	Jul. 27, 2020	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jul. 27, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Feb. 20, 2020	Dec. 19, 2017	Dec. 31, 2015
Stockholders' Equity [Line Items]
Deemed dividends on common stock recognized																							$ 21,560,000
Warrants to purchase shares of Common Stock																															9,595,002
Exercise of warrants						29,100,000														29,100,000						29,100,000	14,999,998
Proceeds from exercise of warrants																												$ 6,400,000	$ 6,300,000
Shares of common stock issued for the cashless exercise of Warrants																												5,900,000
Cashless exercise of warrants reducing balance owed for notes payable - warrant exchange																												$ 1,300,000
Costs related to the warrant exchange offset against additional paid-in capital																												$ 313,000
Warrants outstanding	0	0																			0	0				0		0	0
Preferred Stock, Shares Authorized	1,000,000	1,000,000																			1,000,000	1,000,000				1,000,000		1,000,000	1,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001																			$ 0.001	$ 0.001				$ 0.001		$ 0.001	$ 0.001
Cost for issuance of shares																					$ 1,525,000			$ 0
Sale of Stock, Consideration Received on Transaction							$ 4,500,000
Common Stock, Shares Authorized	275,000,000	275,000,000																			275,000,000	275,000,000				275,000,000		275,000,000	275,000,000
Common Stock, Capital Shares Reserved for Future Issuance																					6,500,000
Proceeds from Issuance of Common Stock							$ 4,520,000
Common Stock, Shares, Issued	140,071,110	140,071,110																			180,317,751	140,071,110				140,071,110		140,071,110	140,071,110
Proceeds from Warrant Exercises																												$ 6,400,000	$ 6,300,000
Stock Issued During Period, Shares, Warrants Exercised						29,100,000														29,100,000						29,100,000	14,999,998
Series A Warrants [Member]
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)							25,000,000
Exercise of warrants																											3,300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.22
Number of stocks sold							1
Number of warrants issued							25,000,000
Exercise price of warrants							$ 0.22
Term of the warrants							2 years
Stock Issued During Period, Shares, Warrants Exercised																											3,300,000
Series B Warrants [Member]
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)							25,000,000
Exercise of warrants																											6,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.22
Number of stocks sold							1
Number of warrants issued							25,000,000
Exercise price of warrants							$ 0.22
Term of the warrants							7 years
Stock Issued During Period, Shares, Warrants Exercised																											6,600,000
Common Stock
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)							2,450,000
Shares Issued, Price Per Share							$ 0.20			$ 0.90
Conversion of Stock, Shares Issued																		28,925,000			5,887,997							22,550,000		2,470,000
Common Stock, Shares Authorized																																275,000,000
Shares, Outstanding	140,071,000	140,071,000																			180,318,000	140,071,000		24,152,000		140,071,000		140,071,000	140,071,000	20,152,000
Number of stock issued on each unit of stock sold							1
Preferred Tracking Stock
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, Acquisitions													1
Shares exchanged for ownership interest													29,990,000
Noncontrolling Interest, Amount Represented by Preferred Stock													$ 13,000,000
Preferred Stock, Dividend Rate, Percentage																					2.00%
Preferred Stock, Dividends Per Share, Declared																					$ 0
Dividends Payable	$ 871,000	$ 871,000																			$ 937,000	$ 871,000				$ 871,000		$ 871,000	$ 871,000
Preferred Stock [Member]
Stockholders' Equity [Line Items]
Shares, Outstanding	6,000	6,000																				6,000		6,000		6,000		6,000	6,000	10,000
Warrant [Member]
Stockholders' Equity [Line Items]
Number of stocks sold							2
Common Stock and Warrants [Member]
Stockholders' Equity [Line Items]
Shares Issued, Price Per Share							$ 0.20
Preferred Tracking Stock
Stockholders' Equity [Line Items]
Shares exchanged for ownership interest													1
Preferred Stock, Par or Stated Value Per Share													$ 0.001
Series A Preferred Stock [Member]
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)									6,300
Preferred Stock, Shares Authorized										1,000,000
Convertible Preferred Stock, Terms of Conversion																					Each share of Series A Preferred was convertible into an amount of shares of common stock determined by dividing the stated value of $1,000 by the conversion price in effect at such time. The original conversion price of $0.90 was adjusted to $0.20 upon the closing of the Company's public offering on October 29, 2019
Dividends Payable																					$ 0
Preferred Stock, Par or Stated Value Per Share										$ 0.001
Conversion of Stock, Shares Converted																													3,987	2,223
Preferred Stock, Shares Outstanding	0	0																			0	0				0		0	0
Share Price										$ 1,000
Series B Preferred Stock [Member]
Stockholders' Equity [Line Items]
Maximum Common Stock Percentage										48.00%
Preferred Stock, Shares Authorized	5,785	5,785								1,000,000											5,785	5,785				5,785		5,785	5,785
Convertible Preferred Stock, Terms of Conversion																					Each share of Series B Preferred was convertible into an amount of shares of common stock determined by dividing the stated value of $1,000 by the conversion price in effect at such time. The original conversion price of $0.90 was adjusted to $0.20 upon the closing of the Company's public offering on October 29, 2019. See the section below entitled "Public Offering - October 29, 2019" for further information. The number of shares of common stock to be received was limited by the beneficial ownership limitation as defined in the certificate of designation. Subject to limited exceptions, a holder of Series B Preferred would not have the right to exercise any portion of its Series B Preferred if such holder, together with its affiliates, would beneficially own over 48% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
Dividends Payable																					$ 0
Preferred Stock, Par or Stated Value Per Share										$ 0.001
Shares Issued, Price Per Share							$ 0.20			0.90
Conversion of Stock, Shares Converted	5,785								5,785
Preferred Stock, Shares Outstanding	5,785	5,785																			0	5,785				5,785		5,785	5,785
Share Price										$ 1,000
Series C Preferred Stock [Member]
Stockholders' Equity [Line Items]
Maximum Common Stock Percentage								4.99%
Issuance of common stock to underwriters (in shares)							4,510
Preferred Stock, Shares Authorized								1,000,000
Convertible Preferred Stock, Terms of Conversion																					Each share of Series C Preferred was convertible into an amount of shares of common stock determined by dividing the stated value of $1,000 by the conversion price of $0.20, subject to adjustment. The number of shares of common stock to be received was limited by the beneficial ownership limitation as defined in the certificate of designation. Subject to limited exceptions, a holder of Series C Preferred would not have the right to exercise any portion of its Series C Preferred if such holder, together with its affiliates, would beneficially own over 4.99% (or, upon election by a holder prior to the issuance of any Series C Preferred Shares, 9.99)% of the number of shares of our common stock outstanding immediately after giving effect to such exercise; provided, however, that upon prior notice to us, such holder may increase such limitation, provided that in no event will the limitation exceed 9.99% and any such increase would not be effective until the 61st day after such notice was delivered to the Company.
Dividends Payable								$ 0
Preferred Stock, Par or Stated Value Per Share								$ 0.001
Common Stock, Par or Stated Value Per Share								1,000
Shares Issued, Price Per Share								$ 0.20
Conversion of Stock, Shares Converted							4,510
Preferred Stock, Shares Outstanding	0	0																			0	0				0		0	0
Maximum ownership through conversion without prior notice, prior to the issuance of preferred shares								9.99%
Series C Preferred Shares, and Warrants [Member]
Stockholders' Equity [Line Items]
Shares Issued, Price Per Share							$ 1,000
Underwritten offering
Stockholders' Equity [Line Items]
Proceeds from Issuance of Common Stock							$ 5,000,000
Eastern Share Purchase Agreements [Member]
Stockholders' Equity [Line Items]
Term of agreement									2 years					3 years
Maximum Common Stock Percentage											48.00%	38.00%					38.00%
Issuance of common stock to underwriters (in shares)														650,000	650,000		650,000
Proceeds from exercise of warrants																	$ 945,000
Stock Issued During Period, Shares, Acquisitions																	350,000
Shares Issued, Price Per Share																	$ 6.22
Stock Issued During Period, Value, New Issues														$ 4,043,000		$ 2,177,000
Equity Method Investment, Ownership Percentage												40.00%
Agreement term									2 years					3 years
Class Of Warrants Or Rights Exercised																178,400
Proceeds from Warrant Exercises																	$ 945,000
iBio CDMO LLC
Stockholders' Equity [Line Items]
Shares exchanged for ownership interest													1
Eastern Affiliate
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)																	650,000
Equity Method Investment, Ownership Percentage											40.00%
Lincoln Park Capital Fund, LLC [Member]
Stockholders' Equity [Line Items]
Proceeds from Issuance of Common Stock																						$ 18,440,000
Preferred Tracking Stock
Stockholders' Equity [Line Items]
Stock Issued During Period, Value, New Issues													$ 13,000,000
UBS Securities, LLC ("UBS")
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)	2,360,000	17,420,000																			10,410,000
Cost for issuance of shares		$ 1,270,000
Commission rate			3.00%
Reimbursement of fees and disbursements			$ 50,000
Sale of Stock, Consideration Received on Transaction			$ 72,000,000
Proceeds from Issuance of Common Stock	$ 5,550,000	$ 37,840,000																			$ 26,850,000
iBio CMO
Stockholders' Equity [Line Items]
Shares exchanged for ownership interest													29,990,000
Noncontrolling Interest, Amount Represented by Preferred Stock																	$ 15,000,000
Noncontrolling Interest, Ownership Percentage by Parent													99.99%																				100.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners																	70.00%				30.00%
iBio CMO \| Preferred Tracking Stock
Stockholders' Equity [Line Items]
Acquisition Of Equity Interest, Units Receivable Per Preferred Share																					29,990,000
iBio CMO \| Preferred Tracking Stock \| Scenario Two
Stockholders' Equity [Line Items]
Shares exchanged for ownership interest													29,990,000
iBio CMO \| Eastern Affiliate
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners													0.01%								70.00%
Preferred Tracking Stock
Stockholders' Equity [Line Items]
Stock Issued During Period, Value, New Issues													$ 13,000,000
Convertible Preferred Stock, Shares Issued upon Conversion													29,990,000
Lincoln Park 2020 Purchase Agreement
Stockholders' Equity [Line Items]
Term of agreement					36 months
Maximum obligation under each Regular Purchase					$ 5,000,000
Floor price					$ 0.20
Maximum Common Stock Percentage					19.99%
Issuance of common stock to underwriters (in shares)				1,000,000	815,827														2,673,000			16,800,000			19,470,000
Common Stock, Par or Stated Value Per Share					$ 0.001
Shares Issued, Price Per Share				$ 1.09
Maximum ownership through conversion without prior notice					9.99%
Stock Issued During Period, Value, New Issues				$ 1,100,000
Proceeds from Issuance of Common Stock																			$ 6,790,000						$ 25,230,000
Aggregate Common Stock Purchased					$ 50,000,000
Agreement term					36 months
Sale Of Stock Number Of Shares Offered For Sale					1,000,000
Linco ln Park May 2020 Purchase Agreement \| Securities and Exchange Commission
Stockholders' Equity [Line Items]
Issuance of common stock to underwriters (in shares)				1,000,000
Shares Issued, Price Per Share				$ 1.09
Stock Issued During Period, Value, New Issues				$ 1,090,000